Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy

Abstract

In recent years, polymeric nanoparticles have appeared as a most viable and versatile delivery system for targeted cancer therapy. Various in vivo studies have demonstrated that virus-sized stealth particles are able to circulate for a prolonged time and preferentially accumulate in the tumor site via the enhanced permeability and retention (EPR) effect (so-called "passive tumor-targeting"). The surface decoration of stealth nanoparticles by a specific tumor-homing ligand, such as antibody, antibody fragment, peptide, aptamer, polysaccharide, saccharide, folic acid, and so on, might further lead to increased retention and accumulation of nanoparticles in the tumor vasculature as well as selective and efficient internalization by target tumor cells (termed as "active tumor-targeting"). Notably, these active targeting nanoparticulate drug formulations have shown improved, though to varying degrees, therapeutic performances in different tumor models as compared to their passive targeting counterparts. In addition to type of ligands, several other factors such as in vivo stability of nanoparticles, particle shape and size, and ligand density also play an important role in targeted cancer chemotherapy. In this review, concept and recent development of polymeric nanoparticles conjugated with specific targeting ligands, ranging from proteins (e.g., antibodies, antibody fragments, growth factors, and transferrin), peptides (e.g., cyclic RGD, octreotide, AP peptide, and tLyp-1 peptide), aptamers (e.g., A10 and AS1411), polysaccharides (e.g., hyaluronic acid), to small biomolecules (e.g., folic acid, galactose, bisphosphonates, and biotin), for active tumor-targeting drug delivery in vitro and in vivo are highlighted and discussed. With promise to maximize therapeutic efficacy while minimizing systemic side effects, ligand-mediated active tumor-targeting treatment modality has become an emerging and indispensable platform for safe and efficient cancer therapy.

Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery

“…To minimize the side effect of the drugs, targetspecific drug delivery techniques were introduced with various surface modifications of drug carriers, based on interactions between targeting moieties and receptors that are specifically over-expressed on the surface of tumor cells. 9 In other words, tumor specificity of anticancer drugs could be significantly enhanced by combining targeting molecules with either the drugs or drug carriers. For example, an arginine-glycine-aspartate (RGD) peptide as a tumor-targeting moiety was conjugated onto the albumin nanoparticles with gemcitabine, inhibiting pancreatic tumor cell growth.…”

Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models

“…Other surface alterations, such as the incorporation of targeting moieties (e.g., antibodies, proteins, polysaccharides, and small molecules) provide enhanced efficacy and selectivity to tumor tissue and cells, thereby enhancing specificity and reducing off-target effects. The active targeting approach takes advantage of the overexpression of certain ligands and receptors on the tumor cell surfaces that permit a molecular recognition and a more efficient uptake of functionalized nanoparticles [35].…”

Functionalized Polymers for Enhance Oral Bioavailability of Sensitive Molecules

“…However, FP-NPs are the most studied systems in molecules delivery, because they increment their cellular uptake through receptor-mediated endocytosis [25]. NPs are also recognized as delivery enhancers systems that provide an added level of protection from degradation of sensitive molecules and assist co-localized release, improving their therapeutic performance.…”